The ongoing debate regarding dietary supplements is intensifying as manufacturers urge the Food and Drug Administration (FDA) to broaden the range of ingredients permissible in their products. This shift could potentially lead to increased promotion of popular items like peptides and probiotics. On Friday, the FDA hosted a public meeting to evaluate its long-standing criteria for dietary supplements and to consider the inclusion of ingredients that do not traditionally arise from food sources, vitamins, or herbs. During the meeting, officials from the FDA listened to insights from industry leaders, consumer advocates, and academics.
This marks the first meeting of its kind since Robert F. Kennedy Jr. took on the role of the nation’s health official last year. Kennedy has committed to “ending the war at the FDA” regarding dietary supplements and other popular products associated with his Make America Healthy Again initiative. The meeting was initiated by the Natural Products Association, an industry group that has had its share of disagreements with the FDA over newly introduced supplement ingredients. The organization outlined the need for a discussion in a letter sent in January, highlighting the “cost and uncertainty” caused by unclear regulatory expectations.
Opening the meeting, Kyle Diamantas, the FDA’s lead official for food regulations, emphasized the administration’s dedication to “reducing red tape” and decreasing industry costs. “The industry has seen remarkable growth over the last 30 years, yet the regulatory framework has remained largely unchanged,” Diamantas informed attendees.
Key Points on the Issue
Many wellness products currently do not qualify as dietary supplements under FDA regulations, which classify supplements as a specific category of food. Most ingredients in these products originate from plants, herbs, and other dietary components commonly found in American cuisine.
This requirement has posed challenges for the industry, especially as newer wellness products often include ingredients not traditionally used in foods. For instance, peptides, which are chains of amino acids often marketed by celebrities and social media influencers for muscle building and anti-aging benefits, lack substantial scientific backing. While many specialty pharmacies and clinics provide these as injections or IV infusions, some supplement manufacturers have begun integrating them into capsules, gummies, and powders.
According to FDA lawyers, these products technically violate existing regulations. The same applies to specific types of probiotics, which are marketed for digestive health and wellness. Companies argue that current FDA laws do not explicitly require all ingredients to derive from food sources.
“The objective of the meeting is to encourage the FDA to reconsider its definition of what a dietary ingredient can be, to potentially include substances not commonly found in foods,” stated Robert Durkin, a former FDA supplements program official now consulting for industry players.
However, consumer advocates express concerns that permitting new ingredients could significantly enlarge the supplement market, an area the FDA has historically struggled to regulate effectively. “The FDA should prioritize making the existing market safer rather than allowing more chemicals and substances into the supplement space,” urged Jensen Jose, senior regulatory counsel at the nonprofit Center for Science in the Public Interest.
Support from Kennedy for Manufacturers
Recently, Kennedy expressed his support for peptides, asserting they have aided him in injury recovery. He also indicated his intention to ease FDA restrictions on the production of injectable peptides, which are subject to federal safety guidelines.
Many of Kennedy’s supporters are also advocates for these compounds, including Gary Brecka, who markets peptide injectables, patches, and nasal sprays on his website. Dr. Mark Hyman, another associate of Kennedy’s, offers numerous dietary supplements, some advertising peptide content, via his online platform.
Additionally, two former health advisors from Kennedy’s presidential campaign have associations with the supplement industry. Calley Means, currently a senior adviser in the Department of Health and Human Services, co-founded an online platform facilitating tax-free spending on health supplements. Meanwhile, Dr. Casey Means, Kennedy’s sister and a nominee for President Donald Trump’s surgeon general, has reportedly earned substantial income promoting supplements and probiotics, according to financial disclosures.
Inadequate FDA Oversight of Supplements
The FDA does not oversee dietary supplements in the same rigorous manner as pharmaceuticals, which must demonstrate safety and efficacy before approval. Currently, the agency does not maintain a comprehensive list of circulating supplement products. With an estimated 100,000 supplements available in the market, manufacturers carry the responsibility for ensuring the safety and truthful marketing of their products. As per FDA guidelines, supplements cannot claim to treat specific diseases or conditions.
The 1994 law that granted the FDA oversight of the supplement industry also exempted manufacturers from nutrition labeling mandates, requiring scientific evidence to support health claims. Instead, manufacturers are permitted to make more general assertions regarding health maintenance and well-being.
Some former regulators believe this lenient approach was misguided. “It allowed for unauthorized health claims to be implied,” stated Mitch Zeller, who was involved with FDA supplement regulations during the 1990s. “Numerous claims on supplement labels and in advertisements are carefully worded to skirt direct assertions of drug or treatment benefits.”
Companies can assert that their products contribute to the improvement of certain bodily structures or functions, such as enhancing bone strength. However, any product making either general or specific claims is obligated to include a disclaimer: “This statement has not been evaluated by the FDA.”
As the discussions continue, the delicate balance between consumer safety and market expansion is expected to remain at the forefront of the regulatory dialogue surrounding dietary supplements. With the ongoing influence of industry lobbyists and the potential for new ingredient approvals, the future of dietary supplements could see significant changes.
